

CRISPR Knockout of the HuR Gene Causes a Xenograft Lethal Phenotype

Shruti Lal^{*1}, Edwin C. Cheung^{*1}, Mahsa Zarei^{*1}, Ranjan Preet², Saswati N. Chand¹, Nicole C. Mambelli-Lisboa¹, Carmella Romeo¹, Matthew C. Stout³, Eric Londin⁴, Austin Goetz¹, Cinthya Y. Lowder¹, Avinoam Nevler¹, Charles J. Yeo¹, Paul M. Campbell³, Jordan M. Winter¹, Dan A. Dixon² and Jonathan R. Brody¹

* Contributed equally (First authors)

¹Department of Surgery, Division of Surgical Research; Jefferson Pancreas, Biliary and Related Cancer Center; Jefferson Medical College; Thomas Jefferson University, Philadelphia, PA, USA

²Department of Cancer Biology and University of Kansas Cancer Center, University of Kansas Medical Center, Kansas City, KS, USA

³Department of Pharmacology and Physiology, Drexel University College of Medicine, Philadelphia, PA, USA

⁴Computational Medicine Center, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia PA, USA

Figure S1: *HuR* inhibition was successfully achieved by CRISPR/cas9 system. A, Schematic of CRISPR/Cas9 single plasmid and flow chart depicting strategy of the experiment. The U6 promoter is driving the expression of gRNA while CMV promoter is driving the expression of Cas9 which is fused with GFP via 2A peptide linkage at C terminus. GFP positive single cells were sorted by FACS analysis and sorted cell population were expanded and assessed for mutation by sequencing and verified by qPCR and western blot. *CRISPR-cas9 system successfully knockout *HuR* expression.* B, Relative *HuR* mRNA expression in all the clones was assessed by qPCR in MIA PaCa-2. C, Relative protein expression of *HuR* was assessed in all the clones by western blot in MIA PaCa-2. D, Sanger sequencing validation of mutation in Hs 766T CRISPR clones. E, Immunoblot showing complete *HuR* inhibition after CRISPR knockout in Hs 766T CRISPR clones.




Figure S1

Figure S2: *HuR* inhibition sensitizes cells to drugs. Drug sensitivity (7-day short-term cell survival) on MIA.HuR.WT^(+/+), MIA.HuR.KO^(+/+) and MIA.HuR.KO^(-/-) using A, mitomycin C (MMC) and B, Glucose deprivation (low glucose). C and D, MIA.HuR.WT^(+/+) and MIA.HuR.KO^(-/-) cells ability to transform from 2D to 3D cultures (i.e., organoids). Error Bars: 95% CI.




Figure S2

Figure S3: PDA xenografts with HuR inhibition failed to form tumors. A, Representative images of subcutaneous tumors on the flanks of nude female mice and their corresponding excised tumors (day 46). B, Tumor growth curves of MIA.HuR.WT^(+/+), MIA.HuR.KO^(+/+), MIA.HuR.KO^(-/-).1 and MIA.HuR.KO^(-/-).2 xenografts in nude mice. Data represent means \pm SEM of $n = 5$. ns, non-significant, * $p < 0.001$, ** $p < 0.0003$.




Figure S3

Table S1: Lists the three guide RNAs used to generate CRISPR knockout of HuR in MIA PaCa-2 and Hs 766T cell lines.

Gene Name	RefSeq ID	Exon Position	Nucleotide position in RefSeq	Guide RNA Sequence	Strand
ELAVL1 (Guide RNA 1)	NM_001419	2	188	GCCGAAGACTGCAGG	5'-N19NGG_sense
ELAVL1 (Guide RNA 2)	NM_001419	2	263	CCAGGATGAGTTACG	5'-N19NGG_antisense
ELAVL1 (Guide RNA 3)	NM_001419	3	363	ACGTGACCGCGAAGG	5'-N19NGG_sense

Table S2: Lists the primers used to detect the mutation created by all three guide RNAs in CRISPR knockout of HuR MIA PaCa-2 and Hs 766T cell lines.

Primers	Sequence
Guide RNA 1-Forward-1	TTGGGAACTTATGTCCGATCT
Guide RNA 1-Reverse-1	GCAGTTACTAGTTTTGCCTTCATA
Guide RNA 1-Forward-2	CGATCAAATTCGTTCTCCCG
Guide RNA 1-Reverse-2	GCATAGAAAAGAATCTCTAAGTGC
Guide RNA 2-Forward-1	CACGTGGGACCCAATCAATC
Guide RNA 2-Reverse-1	GTGACATCGGGAGAACGAAT
Guide RNA 3-Forward-1	GAGCTGACGCAACCTGG
Guide RNA 3-Reverse-1	AAGGCCAGGCAGATATAGTG
Guide RNA 3-Forward-2	CACTCATGTAAGGCCTGGGT
Guide RNA 3-Reverse-2	GGAACCTGTGTTTCATTGCAGA
Guide RNA 3-Forward-3	TTTACTGTCTGCACCCCGA
Guide RNA 3-Reverse-3	CCTCACTCGCAGACGGTTG

Table S3: Lists the clones along with their genotypes obtained for all three guide RNAs. All mutations were confirmed by Sanger sequencing. Wild Type: No mutation in both the alleles; and Homozygous Mutant: Both alleles have either same or different mutations.

		Clone	Genotype
Guide RNA 1	}	Clone.1	Wild Type (+/+)
		Clone.2	Wild Type (+/+)
		Clone.3	Wild Type (+/+)
		Clone.4	Wild Type (+/+)
Guide RNA 2	}	Clone.5	Wild Type (+/+)
		Clone.6	Wild Type (+/+)
		Clone.7	Wild Type (+/+)
		Clone.8	Wild Type (+/+)
Guide RNA 3	}	Clone.9	Wild Type (+/+)
		Clone.10	Homozygous Mutant (-/-)
		Clone.11	Homozygous Mutant (-/-)
		Clone.12	Wild Type (+/+)
		Clone.13	Homozygous Mutant (-/-)
		Clone.14	Homozygous Mutant (-/-)
		Clone.15	Homozygous Mutant (-/-)
		Clone.16	Wild Type (+/+)

Table S4: Lists the cell lines produced along with their mutations and chromatograms obtained through Sanger sequencing. WT: Wild Type - No mutation in both the alleles.

Cell Lines	HGVS Nomenclature	Sequence Chromatogram
MIA PaCa2: MIA.HuR-KO ^(+/+) (Clone.4)	NM_001419 ^[WT]	
MIA PaCa2: MIA.HuR-KO ^(-/-) .1 (Clone.11)	NM_001419[c.211delCG];[c.211delCG]	
MIA PaCa2: MIA.HuR-KO ^(-/-) .2 (Clone.14)	NM_001419[c.204delGTGACCGGA];[c.206delGACCGGAAGGATGCAG]	
Hs 766T: HsT.HuR-KO ^(-/-)	NM_001419[c.211_212insATGATAGTCCATTTTAA AACATAATTTTAAACTGCAAACACTAC]; [c.211_212insATGATAGTCCATTTTAAACATAATTTTAA AACTGCAAACACTAC]	